Atlas Trials

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Clinical trial NCT05484583 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05484583
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung CancerExtensive-stage Small-cell Lung CancerRadiotherapy
Start date
2022-08-01
Primary completion
2024-08-01
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.